Hypertension
Conditions
Brief summary
First of all to evaluate the relationship between non-conventional biomarkers and essential hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood pressure control and non-conventional biomarkers in naive hypertensive patients
Interventions
Sponsors
Fondazione IRCCS Policlinico San Matteo di Pavia
University of Pavia
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* essential hypertension * naive to treatment * \< 65 years
Exclusion criteria
* secondary hypertension * previous cardiovascular events
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blood pressure reduction | 5 years | * Systolic Blood Pressure (SBP) * Diastolic Blood Pressure (DBP) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular and metabolic biomarkers | 5 years | * Lipoprotein (a) (Lp(a)) * sRAGE (soluble Receptor for Advanced Glycation End-products) * sCD40L (soluble ligand of CD40) * MPO (myeloperoxidase) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of vascular stiffness | 5 years | \- Aortic Pulse Wave velocity (PWV) |
Countries
Italy
Contacts
Primary ContactGiuseppe Derosa, MD, PhD
Backup ContactAmedeo Mugellini, MD, PhD
Outcome results
None listed